- USDA Gets Tougher on Salmonella in Raw Breaded Chicken Products
- Fragments of Bird Flu Virus Found in 1 in 5 Milk Samples
- Clients Got HIV Through ‘Vampire Facial’ Microneedling Treatments
- Take the Stairs & Step Up to Longer Life
- ‘Drug Take Back Day’ is Saturday: Check for Leftover Opioids in Your Home
- Loneliness Can Shorten Lives of Cancer Survivors
- A Stolen Dog Feels Like Losing a Child, Study Finds
- Healthier Hearts in Middle Age Help Black Women’s Brains Stay Strong
- Better Scans Spot Hidden Inflammation in MS Patients
- Which Patients and Surgeries Are ‘High Risk’ for Seniors?
Vimizim Approved for Rare Childhood Disorder
Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.
The disorder is caused by a missing metabolic enzyme that leads to problems with bone development, growth and movement, the agency said in a news release. It affects about 800 people in the United States.
Vimizim replaces the missing enzyme, known as GALNS. The drug’s safety and effectiveness were established in clinical trials involving 176 people, ranging in age from 5 to 57. The most common side effects included fever, vomiting, headache, nausea, abdominal pain, chills and fatigue, the FDA said.
The drug’s safety and effectiveness weren’t evaluated in children under age 5 years, the agency added. Vimizim’s label will include a boxed warning to include the risk of anaphylaxis, an allergic-like reaction that could be life threatening.
Vimizim was the first drug granted a Rare Pediatric Disease Priority Review Voucher, an FDA effort to encourage development of new treatments for rare childhood diseases.
The drug is marketed by BioMarin Pharmaceuticals, based in Novoto, Calif.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.